PHASE I AND PHARMACOKINETIC STUDIES OF ANTICANCER AGENTS

抗癌药物的 I 期研究和药代动力学研究

• 批准号: 3607840
• 负责人: Ross C Donehower
• 金额: $ 6.83万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1990
• 资助国家: 美国
• 起止时间: 1990-05-01 至 1995-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3607840
• 关键词: antineoplastics; chemical information system; clinical trials; drug adverse effect; drug metabolism; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology; antineoplastics; chemical information system; clinical trials; drug adverse effect; drug metabolism; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer pharmacology

The specific objectives of this contract are: 1) to define the acute toxicities of new anticancer agents with advanced cancer; 2) to redefine the acute toxicities and pharmacokinetics of anticancer administered in combination with agents to modulate toxicity or antitumor effect; 3) to provide information on the pharmacokinetic characteristics (absorption, distribution, metabolism and elimination) and pharmacodynamics of selected antitumor agents; 4) to determine a treatment regimen suitable for evaluation of antitumor activity in Phase II trials.

该合同的具体目标是：1）定义急性 具有晚期癌症的新抗癌药的毒性； 2）重新定义 抗癌的急性毒性和药代动力学 与药物结合调节毒性或抗肿瘤作用； 3）到 提供有关药代动力学特征的信息（吸收， 分布，新陈代谢和消除）和药效学 选定的抗肿瘤剂； 4）确定适合治疗方案 用于评估II期试验中的抗肿瘤活性。